Antisoma adds more positive data for AS1404

Antisoma is adding more positive data for its closely-watched lung cancer therapy AS1404. Lung cancer patients taking the treatment with chemotherapy experienced greater delays for tumor progression than had been reported earlier. In the trial, tumor response rates hit 31 percent with AS1404 as compared to 22 percent for chemo alone. Antisoma has been in talks to sign a licensing partner for the therapy, which is headed for Phase III next year. Antisoma says AS1404 can compete with Avastin. If they're right, it would be a blockbuster.

- here's the AFX report on the data

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.